SCHEMBL20093530

SCHEMBL20093530

CC(C)CC(NC(=O)C(Cc1ccccc1)NC(=O)c1cnccn1)B1OC(C)(CCCCCCNOC(=O)c2ccccc2)CN1C

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PSMB5 P28074 16/20 0.52
▸ PSMB1 P20618 11/20 0.47
▸ PSMB2 P49721 10/20 0.47
▸ PSMB8 P28062 10/20 0.47
▸ PSMB9 P28065 10/20 0.47
▸ PSMB6 P28072 10/20 0.47
▸ PSMB10 P40306 10/20 0.47
▸ PSMB11 A5LHX3 9/20 0.47
▸ PSMA7 O14818 9/20 0.47
▸ PSMA1 P25786 9/20 0.47
▸ PSMA2 P25787 9/20 0.47
▸ PSMA3 P25788 9/20 0.47
▸ PSMA4 P25789 9/20 0.47
▸ PSMA5 P28066 9/20 0.47
▸ PSMB4 P28070 9/20 0.47
▸ PSMB3 P49720 9/20 0.47
▸ PSMA6 P60900 9/20 0.47
▸ PSMA8 Q8TAA3 9/20 0.47
▸ PSMB7 Q99436 9/20 0.47
▸ LONP1 P36776 8/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20365884 1.00 PSMB5 (0.52) PSMB5PSMB1PSMB2PSMB8PSMB9
SCHEMBL13130829 0.90 PSMB5 (0.56) PSMB5PSMB1PSMB2PSMB8PSMB9
SCHEMBL464426 0.90 PSMB5 (0.56) PSMB5PSMB1PSMB2PSMB8PSMB9
SCHEMBL14754748 0.90 PSMB5 (0.56) PSMB5PSMB1PSMB2PSMB8PSMB9
SCHEMBL20093548 0.90 PSMB5 (0.56) PSMB5PSMB1PSMB2PSMB8PSMB9
SCHEMBL20093580 0.88 PSMB5 (0.56) PSMB5PSMB1PSMB2PSMB8PSMB9
SCHEMBL13130831 0.88 PSMB5 (0.56) PSMB5PSMB1PSMB2PSMB8PSMB9
SCHEMBL21558228 0.88 PSMB5 (0.56) PSMB5PSMB1PSMB2PSMB8PSMB9
SCHEMBL464475 0.88 PSMB5 (0.56) PSMB5PSMB1PSMB2PSMB8PSMB9
SCHEMBL14712307 0.88 PSMB5 (0.52) PSMB5PSMB1PSMB2PSMB8PSMB9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200323889-A1 CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY CERULEAN PHARMA INC. 2020-10-15 — — US disclosed
US-20200046845-A1 CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY CERULEAN PHARMA INC. 2020-02-13 — — US disclosed
EP-3566719-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASES Cerulean Pharma Inc. (US) 2019-11-13 — — EP disclosed
US-20180110791-A1 CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY CERULEAN PHARMA INC. 2018-04-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180110791-A1 CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY PSMG3, COPB1, PSMA6 PSMB5 18/4885PSMB1 6/4885PSMB2 16/4885
US-20200323889-A1 CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY PSMG3, COPB1, PSMA6 PSMB5 18/4885PSMB1 6/4885PSMB2 16/4885
US-20200046845-A1 CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY CDR2, DDOST, GALC PSMB5 1902/4885PSMB1 2386/4885PSMB2 2374/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback